Daniel Chong, MD
Hematology & Oncology · Fairfax, VANPI 1942462601
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (38.6%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 38 manufacturers reported payments, led by Seagen Inc. at 44.7% of the total. Reporting peaked in 2019 at $11,680 and has fallen 92.1% since, to $927 in 2025. Among hematology & oncology clinicians in VA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 150 payments — averaging $97.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Seagen Inc.$7K
- Johnson & Johnson$5K
- AstraZeneca$314
- Amgen$244
- Gilead$208
- Novartis$190
- plus $2K from 32 others
Across 46 payments — averaging $5951.41 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$170K
- Genentech, Inc.$87K
- Seagen Inc.$15K
- Eli Lilly$2K
- AstraZeneca$187
What the payments were for
- Consulting fees$3,36023%
- Speaking & faculty fees$5,67039%
- Travel & lodging$2,03514%
- Food & beverage$3,44523%
- Education$1771%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Seagen Inc. | 5 | $6,572 |
| Johnson & Johnson | 25 | $5,216 |
| AstraZeneca(2 entities) | 11 | $314 |
| Amgen | 11 | $244 |
| Gilead | 5 | $208 |
| Novartis | 8 | $190 |
| Daiichi Sankyo Inc. | 8 | $174 |
| E.r. Squibb & Sons, L.L.C. | 8 | $173 |
| Pfizer | 8 | $161 |
| AbbVie | 4 | $115 |
| Merck | 6 | $112 |
| GSK | 5 | $104 |
| Astellas Pharma US Inc | 4 | $93 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $85 |
| Rigel Pharmaceuticals, Inc. | 3 | $80 |
| Exelixis Inc. | 3 | $79 |
| Genentech USA, Inc. | 3 | $75 |
| Ipsen Biopharmaceuticals, Inc | 3 | $72 |
| Bristol Myers Squibb | 3 | $71 |
| Incyte Corporation | 2 | $48 |
| Array Biopharma Inc | 2 | $45 |
| Coherus Oncology, Inc. | 2 | $37 |
| Iovance Biotherapeutics, Inc. | 1 | $36 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $35 |
| Myriad Genetic Laboratories, Inc. | 1 | $34 |
| Organon | 2 | $33 |
| Genmab U.S., Inc. | 1 | $32 |
| Regeneron Healthcare Solutions, Inc. | 1 | $31 |
| Eisai Inc. | 2 | $30 |
| Beigene USA, Inc. | 1 | $27 |
| Stemline Therapeutics Inc. | 1 | $27 |
| Agios Pharmaceuticals, Inc. | 1 | $23 |
| Puma Biotechnology, Inc. | 1 | $22 |
| Mirati Therapeutics, Inc. | 1 | $21 |
| EMD Serono, Inc. | 1 | $19 |
| Medtronic | 1 | $19 |
| ADC Therapeutics America, Inc. | 1 | $18 |
| Lilly USA, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,688 in reported general payments places this provider in the 90th percentile of 293 hematology & oncology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BrukinsaZanubrutinib | 42 | $628,527 |
| TagrissoOsimertinib Mesylate | 25 | $408,205 |
| JakafiRuxolitinib Phosphate | 29 | $407,042 |
| Lenalidomide | 20 | $270,858 |
| ImbruvicaIbrutinib | 15 | $230,917 |
| NubeqaDarolutamide | 17 | $226,808 |
| AlecensaAlectinib Hcl | 11 | $204,956 |
| XtandiEnzalutamide | 14 | $183,224 |
| RevlimidLenalidomide | 12 | $183,178 |
| VenclextaVenetoclax | 22 | $171,791 |
| LynparzaOlaparib | 19 | $166,888 |
| Imatinib Mesylate | 45 | $162,745 |
| Abiraterone Acetate | 41 | $94,570 |
| EliquisApixaban | 66 | $46,623 |
| XareltoRivaroxaban | 20 | $17,406 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Beigene USA, Inc.Brukinsa | $27 | $628,52742 claims |
| AstraZenecaTagrisso, Lynparza | $314 | $575,09244 claims |
| Incyte CorporationJakafi | $48 | $407,04229 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $35 | $230,91715 claims |
| Genentech USA, Inc.Alecensa | $75 | $204,95611 claims |
| Astellas Pharma US IncXtandi | $93 | $183,22414 claims |
| Bristol Myers SquibbRevlimid | $71 | $183,17812 claims |
| AbbVieVenclexta | $115 | $171,79122 claims |
| PfizerEliquis | $161 | $46,62366 claims |
| Johnson & JohnsonXarelto | $5,216 | $17,40620 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 293 hematology & oncology providers in Virginia.
Other hematology & oncology in Fairfax
- William ErshlerFairfax$139K
- Sekwon JangFairfax$56K
- Raymond WadlowFairfax$30K
- Mohamad SalkeniFairfax$12K
- Ruby KochharHampton$236K
- Victor YazbeckRichmond$190K
- David ChangNewport News$141K
- Yue ZhangVirginia Beach$105K
- Jerome GoldschmidtChristiansburg$105K
- Attique SamdaniRichmond$104K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.